|DRUG NAME/ MANUFACTURER||PROPOSED USE||HOW IT WORKS||WHAT’S IMPORTANT|
|donepezil transdermal system (Adlarity) / Corium||Dementia of the Alzheimer's type||Once-weekly transdermal patch formulation of donepezil (a cholinesterase inhibitor). Donepezil is the most commonly prescribed medication to treat the symptoms caused by Alzeimers Disease (AD). Currently, donepezil is only available in tablets administered once daily and the most common side effects are gastrointestinal. By delivering donepezil through the skin, Adlarity has the potential to reduce gastrointestinal side effects.||Route of administration: Transdermal patch
Benefit coverage: Pharmacy
Anticipated FDA decision: 7/30/2020
|filgotinib / Galapagos/Gilead||Rheumatoid arthritis||Janus-associated kinase (JAK)-1 inhibitor that will compete with other oral JAK inhibitors including Xeljanz/Xeljanz XR, Olumiant, and Rinvoq.||Route of administration: Oral
Benefit coverage: Pharmacy, Specialty
Anticipated FDA decision: 8/19/2020
Estimated cost: $30,000 per year
|valoctocogene roxaparvovec / BioMarin Pharmaceutical, Inc.||Hemophilia A||One-time gene therapy treatment designed to replace the missing gene that causes hemophilia A, thereby restoring normal blood clotting function and eliminating the need for lifelong factor replacement therapy. Hemophila A affects about 16,000 Americans with 400 male births per year.||Route of administration: IV injection
Benefit coverage: Medical, Specialty
Anticipated FDA decision: 8/21/2020
Estimated cost: $2-3M
|Viaskin peanut / DBV Technologies||Desensitization treatment of peanut allergy in pediatric patients aged four to 11 years||Transdermal system that delivers small amounts of peanut protein to help desensitize patients to this protein to help avoid potentially life-threatening allergic reactions||Route of administration: Transdermal patch
Benefit coverage: Pharmacy
Anticipated FDA decision: 8/5/2020
Global sales forecast in 2024: $615 million
Benefit coverage is based on currently available information and could change pending final FDA-approved prescribing information.
Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. Some plans require use an in-network pharmacy for prescriptions to be covered. Coverage is subject to any plan deductible, copayment and/or coinsurance requirements. Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and complete details of prescription drug coverage, contact a Cigna representative.
All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, (CHLIC), Cigna Behavioral Health, Inc., Cigna Health Management, Inc., Accredo Health Group, Inc., Express Scripts, Inc., ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., Lynnfield Drug, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC). The Cigna name, logo, and other Cigna marks are trademarks of Cigna Intellectual Property, Inc. "Express Scripts" is a trademark of Express Scripts Strategic Development, Inc. This newsletter is not intended for residents of New Mexico.
© 2020 Cigna. All rights reserved